Stock Analysis on Net

Merck & Co. Inc. (NYSE:MRK)

$24.99

Analysis of Goodwill and Intangible Assets

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Goodwill and Intangible Asset Disclosure

Merck & Co. Inc., balance sheet: goodwill and intangible assets

US$ in millions

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Goodwill
Product rights
IPR&D
Trade names
Licenses and other
Other acquired intangibles, gross carrying amount
Accumulated amortization
Other acquired intangibles, net
Goodwill and other intangibles

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The composition of goodwill and intangible assets exhibits notable shifts over the five-year period. Overall, a fluctuating pattern is observed, with a general decline from 2021 to 2023 followed by increases in 2024 and 2025.

Goodwill
Goodwill remained relatively stable between 2021 and 2023, fluctuating within a narrow range around US$21.2 billion. A modest increase to US$21.668 billion was recorded in 2024, followed by a slight decrease to US$21.579 billion in 2025. This suggests limited impairment charges or new acquisitions significantly impacting goodwill during this period.
Product Rights
Product rights demonstrate a substantial upward trend. Starting at US$23.671 billion in 2021, the value remained relatively consistent through 2023. A significant increase is evident in 2024, reaching US$29.988 billion, and continues to rise sharply in 2025 to US$42.038 billion. This suggests substantial investment in, or acquisition of, product-related intellectual property.
IPR&D
IPR&D (In-Process Research and Development) experienced a consistent decline from US$9.281 billion in 2021 to US$6.816 billion in 2023. This trend reverses in 2024 and 2025, but the values remain significantly lower than earlier years, stabilizing at US$430 million and US$427 million respectively. This indicates a reduction in ongoing research and development projects recorded as in-process.
Trade Names
Trade names remained remarkably constant throughout the period, holding steady at US$2.882 billion from 2021 to 2024 and then at US$2.881 billion in 2025. This suggests no significant changes in the valuation of established brand names.
Licenses and Other
Licenses and other intangible assets show a consistent upward trend, increasing from US$6.604 billion in 2021 to US$10.064 billion in 2025. This indicates growing investment in, or acquisition of, licensed technologies and other intangible rights.
Other Acquired Intangibles
The gross carrying amount of other acquired intangibles demonstrates a moderate fluctuation, increasing from US$42.438 billion in 2021 to US$42.162 billion in 2024, and then rising to US$55.410 billion in 2025. However, accumulated amortization has increased consistently throughout the period, from -US$19.505 billion in 2021 to -US$28.729 billion in 2025. Consequently, the net value of other acquired intangibles decreased from US$22.933 billion in 2021 to US$16.370 billion in 2024, before increasing to US$26.681 billion in 2025. The increase in gross carrying amount in 2025, coupled with continued amortization, suggests new acquisitions or revaluations.
Total Goodwill and Intangibles
The aggregate value of goodwill and other intangibles decreased from US$44.197 billion in 2021 to US$38.038 billion in 2024, reflecting the declines in several intangible asset categories. However, a substantial increase is observed in 2025, reaching US$48.260 billion, driven primarily by the significant growth in product rights and other acquired intangibles.

Adjustments to Financial Statements: Removal of Goodwill

Merck & Co. Inc., adjustments to financial statements

US$ in millions

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Adjustment to Total Assets
Total assets (as reported)
Less: Goodwill
Total assets (adjusted)
Adjustment to Total Merck & Co., Inc. Stockholders’ Equity
Total Merck & Co., Inc. stockholders’ equity (as reported)
Less: Goodwill
Total Merck & Co., Inc. stockholders’ equity (adjusted)

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


An examination of the financial information reveals significant adjustments made to total assets and stockholders’ equity, primarily attributable to the removal of goodwill. Reported total assets demonstrate an overall increasing trend from 2021 to 2025, culminating in a value of US$136,866 million. However, adjusted total assets, reflecting the exclusion of goodwill, present a more moderate growth pattern, reaching US$115,287 million in 2025.

Total Asset Impact
The difference between reported and adjusted total assets widens over the period. In 2021, the difference was approximately US$21.264 billion, while by 2025, it had grown to US$21.579 billion. This indicates a substantial amount of goodwill initially present on the balance sheet, which has been subsequently removed through adjustments. The largest absolute increase in reported total assets occurred between 2023 and 2024 (US$10,431 million), while the adjusted total assets increased by US$9,963 million during the same period.

Reported total stockholders’ equity also exhibits an increasing trend, moving from US$38,184 million in 2021 to US$52,606 million in 2025. However, the adjusted stockholders’ equity shows a similar, but less pronounced, pattern of growth, ending at US$31,027 million in 2025.

Stockholders’ Equity Impact
The disparity between reported and adjusted stockholders’ equity also expands over time. The initial difference of approximately US$21,264 million in 2021 grew to US$21,579 million in 2025. This suggests that a significant portion of the reported equity was linked to goodwill. The largest absolute increase in reported stockholders’ equity occurred between 2021 and 2022 (US$7,807 million), while the adjusted stockholders’ equity increased by US$7,867 million during the same period.

The consistent difference between reported and adjusted figures across both total assets and stockholders’ equity strongly suggests a systematic removal of goodwill. The adjustments appear to have a material impact on the reported financial position, indicating that the company’s stated financial health is significantly affected by the accounting treatment of goodwill. The growth rates of the adjusted figures are lower than those of the reported figures, implying that the removal of goodwill moderates the apparent financial expansion.


Merck & Co. Inc., Financial Data: Reported vs. Adjusted


Adjusted Financial Ratios: Removal of Goodwill (Summary)

Merck & Co. Inc., adjusted financial ratios

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Total Asset Turnover
Reported total asset turnover
Adjusted total asset turnover
Financial Leverage
Reported financial leverage
Adjusted financial leverage
Return on Equity (ROE)
Reported ROE
Adjusted ROE
Return on Assets (ROA)
Reported ROA
Adjusted ROA

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The financial metrics demonstrate a significant impact from the adjustment for goodwill and intangible assets. Removing goodwill from the asset base consistently results in substantially different ratios compared to those calculated using reported total assets. Generally, the adjusted ratios suggest a more efficient use of assets and a stronger financial position than indicated by the reported figures.

Total Asset Turnover
Reported total asset turnover fluctuated between 0.46 and 0.56 over the period, with a slight dip to 0.47 in the final year. In contrast, the adjusted total asset turnover exhibited a more pronounced increase from 0.58 in 2021 to a peak of 0.70 in 2023, before declining to 0.56 in 2025. This indicates that, excluding goodwill, the company generates more revenue per dollar of tangible assets.
Financial Leverage
Reported financial leverage showed some variability, ranging from 2.37 to 2.84. The adjusted financial leverage, however, was consistently higher, starting at 4.99 in 2021 and remaining above 3.50 throughout the period. This suggests that the company’s debt is considerably higher relative to its tangible assets when goodwill is excluded from the asset base.
Return on Equity (ROE)
Reported ROE experienced substantial fluctuations, including a significant drop to 0.97 in 2023, followed by a recovery. The adjusted ROE consistently showed much higher values, beginning at 77.12 in 2021 and remaining above 58% throughout the period. The difference highlights the considerable impact of goodwill on reported equity and the resulting ROE calculation. The 2023 drop in reported ROE is significantly less pronounced when goodwill is removed.
Return on Assets (ROA)
Similar to ROE, reported ROA exhibited volatility, with a low of 0.34 in 2023. The adjusted ROA consistently exceeded the reported ROA, starting at 15.46 in 2021 and remaining above 15% for most of the period. This indicates that the company generates a higher return on its tangible assets when goodwill is excluded from the asset base. The impact of the 2023 performance dip is also lessened when goodwill is removed.

In summary, the adjustments for goodwill and intangible assets reveal a substantially different financial picture. The adjusted ratios consistently demonstrate higher asset turnover and profitability, but also a greater degree of financial leverage. The significant differences between reported and adjusted figures underscore the importance of considering the impact of goodwill when evaluating the company’s financial performance and position.


Merck & Co. Inc., Financial Ratios: Reported vs. Adjusted


Adjusted Total Asset Turnover

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Selected Financial Data (US$ in millions)
Sales
Total assets
Activity Ratio
Total asset turnover1
Adjusted for Goodwill
Selected Financial Data (US$ in millions)
Sales
Adjusted total assets
Activity Ratio
Adjusted total asset turnover2

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

2025 Calculations

1 Total asset turnover = Sales ÷ Total assets
= ÷ =

2 Adjusted total asset turnover = Sales ÷ Adjusted total assets
= ÷ =


An examination of the financial information reveals trends in both total asset values and associated turnover ratios over a five-year period. Reported total assets experienced initial growth, followed by a decline and subsequent increase, while adjusted total assets demonstrated a more consistent upward trajectory. The reported and adjusted total asset turnover ratios exhibit differing patterns, suggesting the impact of adjustments made to the asset base.

Reported Total Assets
Reported total assets increased from US$105,694 million in 2021 to US$109,160 million in 2022, representing a growth of approximately 3.3%. A subsequent decrease was observed in 2023, with assets falling to US$106,675 million. Assets then increased significantly in 2024 to US$117,106 million, and continued to rise in 2025, reaching US$136,866 million. This indicates a period of expansion following a temporary contraction.
Adjusted Total Assets
Adjusted total assets showed a steady increase throughout the period. From US$84,430 million in 2021, they grew to US$87,956 million in 2022, US$85,478 million in 2023, US$95,438 million in 2024, and finally reached US$115,287 million in 2025. The decrease in 2023 is less pronounced than the decrease in reported total assets, suggesting the adjustments are mitigating the impact of certain asset categories.
Reported Total Asset Turnover
The reported total asset turnover ratio fluctuated over the five years. It began at 0.46 in 2021, increased to 0.54 in 2022, and further to 0.56 in 2023. A slight decrease to 0.55 was noted in 2024, followed by a more substantial decline to 0.47 in 2025. This suggests a decreasing efficiency in generating revenue from reported assets in the latter year.
Adjusted Total Asset Turnover
The adjusted total asset turnover ratio generally increased from 0.58 in 2021 to a peak of 0.70 in 2023. A slight decrease to 0.67 was observed in 2024, and a more noticeable decline to 0.56 occurred in 2025. While still exhibiting a downward trend in the final year, the adjusted turnover ratio consistently remained higher than the reported turnover ratio throughout the period, indicating that the adjustments to total assets result in a more favorable efficiency metric.

The divergence between the reported and adjusted turnover ratios highlights the significance of the asset adjustments. The consistent increase in adjusted total assets, coupled with a generally higher adjusted turnover ratio, suggests that the adjustments are removing items from the asset base that do not contribute proportionally to revenue generation. The decline in both reported and adjusted turnover ratios in 2025 warrants further investigation to determine the underlying causes.


Adjusted Financial Leverage

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Selected Financial Data (US$ in millions)
Total assets
Total Merck & Co., Inc. stockholders’ equity
Solvency Ratio
Financial leverage1
Adjusted for Goodwill
Selected Financial Data (US$ in millions)
Adjusted total assets
Adjusted total Merck & Co., Inc. stockholders’ equity
Solvency Ratio
Adjusted financial leverage2

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

2025 Calculations

1 Financial leverage = Total assets ÷ Total Merck & Co., Inc. stockholders’ equity
= ÷ =

2 Adjusted financial leverage = Adjusted total assets ÷ Adjusted total Merck & Co., Inc. stockholders’ equity
= ÷ =


An examination of the financial information reveals trends in both reported and adjusted financial leverage over a five-year period. Reported total assets generally increased, with a slight decrease observed between 2022 and 2023 before resuming growth. Reported stockholders’ equity also demonstrated an overall upward trend, though with a decrease from 2022 to 2023, mirroring the asset trend. Adjusted total assets and adjusted stockholders’ equity followed similar patterns, though the magnitudes of change differed. The reported financial leverage ratio exhibited fluctuations, while the adjusted financial leverage ratio consistently remained higher.

Reported Financial Leverage
The reported financial leverage ratio decreased from 2.77 in 2021 to 2.37 in 2022, indicating a reduction in the proportion of assets financed by equity. It then increased to 2.84 in 2023 before decreasing again to 2.53 in 2024. A slight increase to 2.60 was noted in 2025. These fluctuations suggest a dynamic relationship between asset and equity growth, with periods of increased equity outpacing asset growth and vice versa.
Adjusted Financial Leverage
The adjusted financial leverage ratio began at 4.99 in 2021 and decreased to 3.55 in 2022, a more substantial decline than observed in the reported ratio. It rose significantly to 5.22 in 2023, the highest value in the observed period, before decreasing to 3.87 in 2024 and 3.72 in 2025. The higher magnitude of the adjusted ratio, compared to the reported ratio, consistently indicates that the adjustments made to total assets and equity significantly impact the assessment of financial risk. The increase in 2023, followed by declines in subsequent years, suggests a period of increased reliance on debt or other adjustments to assets and equity, followed by a stabilization.
Asset and Equity Trends
Both reported and adjusted total assets increased over the period, although the rate of increase was not consistent. The decrease in both reported total assets and reported stockholders’ equity between 2022 and 2023 is a notable observation. The adjusted figures show a similar pattern, but the magnitude of the decrease in adjusted stockholders’ equity is more pronounced. This suggests that the adjustments made to equity have a greater impact on the overall financial picture during that specific year.

The divergence between reported and adjusted financial leverage highlights the importance of considering the impact of goodwill and intangible assets on a company’s financial risk profile. The adjustments made to both assets and equity result in a substantially different leverage picture than that presented by reported figures alone. The trends suggest a period of fluctuating leverage, with the adjusted ratio consistently indicating a higher level of financial risk than the reported ratio.


Adjusted Return on Equity (ROE)

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Selected Financial Data (US$ in millions)
Net income attributable to Merck & Co., Inc.
Total Merck & Co., Inc. stockholders’ equity
Profitability Ratio
ROE1
Adjusted for Goodwill
Selected Financial Data (US$ in millions)
Net income attributable to Merck & Co., Inc.
Adjusted total Merck & Co., Inc. stockholders’ equity
Profitability Ratio
Adjusted ROE2

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

2025 Calculations

1 ROE = 100 × Net income attributable to Merck & Co., Inc. ÷ Total Merck & Co., Inc. stockholders’ equity
= 100 × ÷ =

2 Adjusted ROE = 100 × Net income attributable to Merck & Co., Inc. ÷ Adjusted total Merck & Co., Inc. stockholders’ equity
= 100 × ÷ =


Analysis of the presented financial information reveals significant discrepancies between reported and adjusted return on equity (ROE) values for the period spanning 2021 to 2025. Stockholders’ equity, both reported and adjusted, demonstrates fluctuations over the five-year period, impacting the observed ROE trends.

Reported Stockholders’ Equity
Reported total stockholders’ equity increased from US$38,184 million in 2021 to US$45,991 million in 2022, representing a substantial rise. A subsequent decrease to US$37,581 million was noted in 2023, followed by increases in both 2024 (US$46,313 million) and 2025 (US$52,606 million). This indicates overall volatility in reported equity.
Adjusted Stockholders’ Equity
Adjusted total stockholders’ equity mirrored the reported equity trend with an increase from US$16,920 million in 2021 to US$24,787 million in 2022. A significant decline occurred in 2023, falling to US$16,384 million, before rising to US$24,645 million in 2024 and further to US$31,027 million in 2025. The magnitude of the fluctuations in adjusted equity is noteworthy.
Reported ROE
Reported ROE exhibited a peak of 34.17% in 2021, followed by a decrease to 31.57% in 2022. A dramatic drop to 0.97% occurred in 2023, before a substantial recovery to 36.96% in 2024 and a slight decrease to 34.70% in 2025. The 2023 value represents a significant outlier compared to other years in the period.
Adjusted ROE
Adjusted ROE began at a high of 77.12% in 2021, decreasing to 58.58% in 2022. A substantial decline to 2.23% was observed in 2023, mirroring the trend in reported ROE. A significant increase to 69.45% occurred in 2024, followed by a decrease to 58.83% in 2025. The adjusted ROE values are considerably higher than the reported ROE values across all years, suggesting a material impact from the adjustments made to stockholders’ equity.

The considerable divergence between reported and adjusted ROE, particularly the low values in 2023 for both metrics, warrants further investigation into the nature of the adjustments made to stockholders’ equity. The fluctuations in both reported and adjusted equity suggest underlying changes in the company’s financial structure or accounting practices. The recovery in both ROE metrics in 2024 and 2025 indicates a potential reversal of the factors contributing to the 2023 decline.


Adjusted Return on Assets (ROA)

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Selected Financial Data (US$ in millions)
Net income attributable to Merck & Co., Inc.
Total assets
Profitability Ratio
ROA1
Adjusted for Goodwill
Selected Financial Data (US$ in millions)
Net income attributable to Merck & Co., Inc.
Adjusted total assets
Profitability Ratio
Adjusted ROA2

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

2025 Calculations

1 ROA = 100 × Net income attributable to Merck & Co., Inc. ÷ Total assets
= 100 × ÷ =

2 Adjusted ROA = 100 × Net income attributable to Merck & Co., Inc. ÷ Adjusted total assets
= 100 × ÷ =


The analysis reveals distinct trends in both reported and adjusted return on assets (ROA) alongside changes in total asset values over the five-year period. Reported total assets generally increased, with a notable dip in 2023 before recovering and experiencing substantial growth in 2024 and 2025. Adjusted total assets mirrored this pattern, though the magnitude of the decrease in 2023 was less pronounced, and the subsequent increases were similarly significant.

Reported Return on Assets (ROA)
Reported ROA demonstrated an initial increase from 12.35% in 2021 to 13.30% in 2022. A significant decline was then observed in 2023, falling to 0.34%. This was followed by a strong recovery in 2024, reaching 14.62%, and a slight decrease to 13.34% in 2025. The fluctuations suggest a sensitivity to changes in reported asset values and net income.
Adjusted Return on Assets (ROA)
Adjusted ROA exhibited a similar trend to the reported ROA, increasing from 15.46% in 2021 to 16.51% in 2022. It also experienced a substantial decrease in 2023, reaching 0.43%. A robust recovery occurred in 2024, with the adjusted ROA climbing to 17.94%, before decreasing to 15.83% in 2025. The adjusted ROA consistently remained higher than the reported ROA across all periods, indicating that the adjustments made to total assets positively impact profitability metrics.

The convergence of both reported and adjusted ROA in 2023, followed by their parallel recovery in 2024, suggests a common underlying factor influencing performance during those years. The difference between the reported and adjusted ROA highlights the impact of goodwill and intangible assets on the overall financial picture. The adjustments to total assets appear to remove or revalue these items, resulting in a more favorable ROA calculation. The growth in both asset measures in 2024 and 2025, coupled with the ROA trends, suggests effective utilization of assets during the recovery period.